Appendix C of Evolve: The Operating Model AI Demands (Hodgson, 2026) sets out the lifecycle investment postures for portfolio executives — the investment questions, evidence requirements, and divestiture decision criteria that a structured quarterly review should produce for each product in the portfolio. This page draws directly from that framework, written for the executive who conducts the review rather than the CFO who approves its funding output. The companion guide drawn from Appendix B of the same book addresses capital allocation structure and funding model design at the CFO level; this page addresses the governance decisions that precede those conversations.
In Brief
- At Introduction, the right portfolio question is “what evidence would cause you to stop?” — not “what justifies continued funding?”
- At Decline, the right question is “what evidence would cause you to continue?” — most portfolio reviews never ask either.
- Evidence requirements shift at each stage: directional at Introduction, quantitative at Growth, comparative at Maturity, active justification at Decline.
- A product that deteriorates when investment is reduced is already in managed decline, regardless of what the portfolio review says.
Most quarterly portfolio reviews produce status reports rather than funding decisions. The distinction matters because the question a portfolio executive asks determines what evidence the team presents. At Introduction, the instinctive question is “what justifies continued funding?” — which orients the team toward building a case for continuation and filters out signal that would justify stopping. At Decline, the instinctive question is “what justifies stopping?” — which orients the team toward defending sunk costs rather than assessing the actual return on continued investment. Both questions are pointed in the wrong direction (Hodgson, 2026). The right questions are the inverse: at Introduction, “what evidence would cause you to stop?”; at Decline, “what evidence would cause you to continue?” These questions expose the thresholds that actually matter for portfolio governance, and most portfolio reviews never ask either.
The four stage frameworks below apply this logic to each phase of the product lifecycle.
Introduction: What would cause you to stop?
The investment thesis at Introduction is a hypothesis. The product has not yet demonstrated that it solves a problem customers will pay to have solved, or that the solution can be delivered at unit economics that justify scale. The portfolio executive at Introduction is evaluating the quality of the learning process, not the quality of the product (Hodgson, 2026).
Investment questions at Introduction:
- What is the hypothesis, precisely stated?
- What evidence would cause you to invalidate it?
- What is the planned learning agenda for the next funding cycle?
- What is the cost of the learning agenda relative to the value of the information it will produce?
Portfolio reviews skip that last question almost universally. At Introduction, the portfolio executive is funding the acquisition of information, not the delivery of product. The decision is whether the information available at the end of the next funding cycle is worth the cost of acquiring it. A learning agenda that costs more than the option value it creates is not worth funding, regardless of the team’s conviction about the hypothesis.
Evidence that justifies continued funding:
Evidence at Introduction is directional, not conclusive. The portfolio executive is looking for signal that the hypothesis is holding and the learning velocity is sufficient: the number of hypotheses tested per unit of time, the rate at which evidence is supporting or invalidating the thesis, and whether genuine behaviour is being observed rather than stated intent collected. Stated intent is not evidence. A customer saying they would pay for something is not evidence they will; a customer changing their behaviour to accommodate a prototype is (Hodgson, 2026).
Divestiture decision criteria:
The case for stopping at Introduction is clearer than it appears at the time, because it is obscured by the sunk cost of having got there. The criteria are: the hypothesis has been tested and the evidence does not support it; no adjacent hypothesis with sufficient option value has been identified; or a more valuable use of the resources has been identified elsewhere in the portfolio. The absence of definitive failure is not evidence of eventual success — it is evidence that the learning agenda has not been rigorous enough (Hodgson, 2026).
Pivot/pause/persevere/stop at Introduction:
Persevere when the evidence is directionally positive and the learning agenda is clear. Pivot when the evidence is invalidating the current hypothesis but revealing a stronger one — the team’s capability and market insight remain valuable even if the original product framing does not. Pause only when the reason for delay is external and time-bounded: a regulatory change, a platform dependency, a key hire — not when the team has exhausted its ideas. Stop when the hypothesis is exhausted and no pivot is available, or when the opportunity cost of continued allocation exceeds the expected value of the option being preserved (Hodgson, 2026).
Growth: Is the return keeping pace with the investment?
At Growth, product-market fit is confirmed. The portfolio executive is no longer evaluating a hypothesis — they are evaluating a proven model’s ability to scale efficiently. The investment question shifts from learning to returns, and the evidence requirements shift from directional to quantitative (Hodgson, 2026).
Investment questions at Growth:
- Is customer acquisition cost declining as volume increases?
- Is margin expanding or contracting as the product scales?
- Is the growth rate ahead of, at, or behind the capital commitment rate?
- What does the adoption trajectory look like relative to available base size?
That last question is the strategic one. A product growing at 40% per year into a total addressable market that is contracting is not a growth asset in the portfolio sense — the apparent strength of the metric masks an underlying structural problem. The portfolio executive needs the growth rate and the adoption trajectory together to make a reliable funding decision.
Evidence that justifies continued funding:
The portfolio executive at Growth wants evidence that the product can sustain its returns as it scales. That means unit economics improving with volume, customer retention above the threshold required for the growth model to work, and an adoption trajectory that leaves sufficient runway before the available base is reached or the competitive landscape shifts structurally. Evidence that the business model is structurally sound at scale is different from evidence that it worked at small scale — a model that performs at 500 customers may not perform at 5,000, and the portfolio review should require evidence of which condition applies (Hodgson, 2026).
Divestiture decision criteria:
At Growth, the case for reducing or exiting a position is not about failure — it is about opportunity cost and strategic fit. The criteria are: growth rate persistently below the capital commitment rate despite operational intervention; margin compression with no clear structural inflection point; a substitute solution capturing adoption at a rate that cannot be matched with available resources; or a strategic shift in the portfolio that makes this product’s growth trajectory less valuable than an alternative use of the same capital. Growth-stage divestiture decisions are made early enough to redeploy resources into higher-return positions; waiting for the growth rate to collapse eliminates that option (Hodgson, 2026).
Pivot/pause/persevere/stop at Growth:
Persevere when growth metrics are tracking against plan and the adoption runway is sufficient. Pivot when the product’s core position is sound but the revenue model or audience segment is producing lower returns than an adjacent opportunity the team has the capability to pursue — the question is whether the executive team will accept the disruption of a deliberate pivot at scale. Pause when the growth rate has slowed due to an identifiable external factor that is time-bounded and not structural — a sector-wide slowdown, a temporary regulatory constraint, a supply chain disruption. Stop when the structural economics of the market have shifted in a way that permanently reduces the return on continued investment; the product may still be operationally viable, but holding a declining-return asset as a growth position misallocates capital that belongs elsewhere in the portfolio (Hodgson, 2026).
Maturity: Investment extension or decline subsidy?
At Maturity, growth has plateaued. The product is generating returns, but the trajectory is flat rather than ascending. The investment question shifts again — not to whether to continue funding, but to whether incremental investment is sustaining the mature state or accelerating the transition toward decline (Hodgson, 2026).
Investment questions at Maturity:
- Is incremental investment producing incremental return, or is it maintaining a position that would otherwise erode?
- What is the remaining competitive differentiation, and how long is it defensible?
- Is the customer base growing, stable, or contracting?
- What would happen to margin and customer retention if investment were reduced by 30%?
That 30% question is the diagnostic one. At Maturity, portfolio executives frequently invest to avoid a decline they are already managing. A product whose margin and retention hold when investment is reduced is in genuine maturity — a product that deteriorates when investment is reduced is already in managed decline, whether or not the portfolio review acknowledges that (Hodgson, 2026).
Evidence that justifies continued funding:
At Maturity, the question is whether the product’s margin contribution still justifies its allocation ahead of other uses. That means: margin is stable or improving without increasing investment; customer retention is above the level required to sustain the revenue base; competitive differentiation is observable in customer behaviour, not merely asserted in the product roadmap; and the investment required to maintain the position is less than the return that position generates. When those conditions hold, the mature product earns its continued allocation (Hodgson, 2026).
Divestiture decision criteria:
The divestiture question at Maturity is a comparison, not an absolute. The criteria are: margin contribution below the portfolio’s required return on capital; customer base contraction that cannot be reversed with available investment; competitive position weakening due to structural market change rather than temporary pressure; or the identification of a higher-value use of the resources currently allocated. Divestiture from maturity is often the hardest portfolio decision because the product is still operating, still making money, still employing people — the signal is opportunity cost, not failure, and opportunity cost requires a comparison to make visible (Hodgson, 2026).
Pivot/pause/persevere/stop at Maturity:
Persevere when margin contribution is healthy, competitive differentiation is defensible, and no superior alternative for the capital exists. Pivot when the core product is mature but a capability, customer relationship, or platform built to support it can be redirected toward a growing adjacent opportunity — the product’s lifecycle ends but the investment converts rather than exits. Pause when external disruption to the operating environment appears temporary and the structural economics remain sound. Stop when the structural economics have shifted permanently, the differentiation is no longer defensible, and the opportunity cost of continued allocation is demonstrably higher than the return the product will generate through its remaining lifecycle (Hodgson, 2026).
Decline: What would cause you to continue?
At Decline, the structural trajectory is downward. Revenue and margin are contracting; so is the customer base, in ways that continued investment cannot reverse. The instinctive question — “what justifies stopping?” — is pointed in the wrong direction, because it places the burden of proof on those who want to exit a deteriorating position, rather than on those who want to continue one (Hodgson, 2026). The correct question is the inverse: “what evidence would cause you to continue?”
Investment questions at Decline:
- What evidence would justify continued investment at current levels?
- What is the option value of maintaining a position in this market, and is it quantifiable?
- What is the cost of exit, and how does it compare to the cost and expected return of continuation?
- Is there a strategic asset within the declining product — a technology, a customer relationship, a capability — that has value independent of the product’s commercial trajectory?
The option value question is the one most portfolio executives avoid at Decline because answering it honestly requires admitting that the product’s commercial trajectory is not sufficient justification on its own. If continued investment is only justified by option value, that option value needs to be named, sized, and assessed against the cost of the option being held. An unnamed option is not an option — it is a rationalisation for inaction (Hodgson, 2026).
Evidence that justifies continued funding:
At Decline, the bar for continued funding is active justification, not passive continuation. Evidence that justifies continued investment includes: a time-bounded strategic reason — a major customer contract, a regulatory compliance requirement, a platform dependency that other products rely on — whose value exceeds the cost of maintaining the declining product through that period; a recoverable asset within the product whose extraction requires maintaining it in operation for a defined period; or a pivot thesis with sufficient evidence to constitute a Growth-stage investment rationale, which moves the conversation from Decline to a new Introduction. When none of those conditions apply, continued investment in a declining product is not a funding decision — it is a default (Hodgson, 2026).
Divestiture decision criteria:
The decision to exit at Decline is made when none of the continuation justifications above are present, when their value has been exhausted, or when the cost of continuation exceeds the value of the remaining option. At Decline, the portfolio executive is not deciding whether the product has failed — the market answered that question. The decision is how to manage the exit in a way that preserves the maximum value from the declining asset and redeploys the released resources to higher-value positions in the portfolio. The cost of a well-managed exit is almost always lower than the cost of an exit that is deferred until the product has no remaining value to recover (Hodgson, 2026).
Pivot/pause/persevere/stop at Decline:
Stop is the default at Decline — the question is when, not whether. Stop when continuation justifications have been exhausted and the cost of continued operation exceeds the value of remaining options. Persevere in the narrow case where a time-bounded strategic justification makes continued operation genuinely valuable and that justification is explicitly stated and time-limited. Pivot when the declining product contains an asset — a capability, a technology, a customer relationship — that can be the basis for a new Introduction-stage investment; this is a Decline-to-Introduction transition, not a continuation of the declining product. Pause only when the decline is demonstrably temporary and caused by a reversible external factor — which is rare, because markets that decline structurally tend to accelerate rather than reverse (Hodgson, 2026).
The review question determines what evidence you get
The four-stage framework produces a structurally different portfolio review. Rather than asking every product team to present evidence of progress, the portfolio executive asks each product to present evidence relevant to its current lifecycle stage. The evidence requirements are different for each product in the portfolio, and the decision criteria are explicit rather than emergent from the discussion (Hodgson, 2026).
The structural benefit of the inversion at each end of the lifecycle — “what would cause you to stop?” at Introduction and “what would cause you to continue?” at Decline — is that it forces the portfolio executive to state thresholds before the evidence is presented. A threshold stated in advance is considerably harder to reinterpret when the evidence arrives. The result is a portfolio review that produces funding decisions because the decision criteria were established before the review began, not negotiated during it (Hodgson, 2026).
What this means for senior leaders
- Portfolio governance quality is determined by the questions you establish before evidence is presented, not by how you weigh it once it arrives. Stating decision thresholds in advance is the structural difference between a review that produces funding decisions and one that produces status reports.
- The investment question at Introduction is “what evidence would cause you to stop?” because at Introduction you are funding the acquisition of information, not the delivery of product. The cost of the learning agenda must be compared to the option value of the information it produces — a comparison that cannot be made if the question is framed as justification for continuation.
- At Decline, the burden of proof belongs with those who want to continue investment, not those who want to exit. Option value that cannot be named, sized, and compared to the cost of exit is not a funding rationale — it is rationalisation for inaction (Hodgson, 2026).
- A product whose margin and retention deteriorate when investment is reduced is already in managed decline, regardless of how the portfolio review classifies it. The earlier that reality is stated explicitly, the more capital is available to redeploy into higher-return positions elsewhere in the portfolio.
- Divestiture from maturity is decided on opportunity cost, not operational failure. The comparison — this allocation versus its next best use — does not become visible automatically; the portfolio review must make it explicit for the decision to be made on its actual basis.
References
- Hodgson, M. (2026). Evolve: The operating model AI demands. Zen Ex Machina.
